At the time of writing, Dianthus Therapeutics Inc [DNTH] stock is trading at $22.28, up 3.63%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The DNTH shares have gain 7.43% over the last week, with a monthly amount glided 22.89%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
On October 03, 2024, Oppenheimer initiated with a Outperform rating and assigned a price target of $48 on the stock. Robert W. Baird started tracking the stock assigning a Outperform rating and suggested a price target of $58 on July 26, 2024. Cantor Fitzgerald initiated its recommendation with a Overweight. H.C. Wainwright started tracking with a Buy rating for this stock on May 16, 2024, and assigned it a price target of $40. In a note dated February 15, 2024, Stifel initiated an Buy rating and provided a target price of $44 on this stock.
For the past year, the stock price of Dianthus Therapeutics Inc fluctuated between $13.36 and $32.27. Currently, Wall Street analysts expect the stock to reach $51.5 within the next 12 months. Dianthus Therapeutics Inc [NASDAQ: DNTH] shares were valued at $22.28 at the most recent close of the market. An investor can expect a potential return of 131.15% based on the average DNTH price forecast.
Analyzing the DNTH fundamentals
According to Dianthus Therapeutics Inc [NASDAQ:DNTH], the company’s sales were 6.52M for trailing twelve months, which represents an 33.07% jump. Gross Profit Margin for this corporation currently stands at 1.0% with Operating Profit Margin at -17.96%, Pretax Profit Margin comes in at -15.44%, and Net Profit Margin reading is -15.44%. To continue investigating profitability, this company’s Return on Assets is posted at -0.29, Equity is -0.29 and Total Capital is -0.35. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.0.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 21.71 points at the first support level, and at 21.14 for the second support level. However, for the 1st resistance point, the stock is sitting at 23.03, and for the 2nd resistance point, it is at 23.78.
Ratios To Look Out For
It is important to note that Dianthus Therapeutics Inc [NASDAQ:DNTH] has a current ratio of 15.99. Further, the Quick Ratio stands at 15.99, while the Cash Ratio is 0.6. Considering the valuation of this stock, the price to sales ratio is 109.90, the price to book ratio is 2.18.
